We can accelerate a cure for Alzheimer's

Since the first cases were diagnosed in 1981, 1.8 million Americans have been diagnosed with HIV/AIDS. A positive diagnosis was once thought to be a death sentence and the disease was considered one of the greatest public health crises ever.

In response, the federal government poured massive resources into developing treatments and now, thanks to pharmacological and other research, HIV/AIDS is considered a chronic but no longer life-threatening condition.

ADVERTISEMENT

By comparison, 5.8 million Americans today are battling Alzheimer’s disease, with a new case being diagnosed every 65 seconds.

By 2050, the number of people age 65 and older with Alzheimer’s will grow to a projected 14 million, in the absence of medical breakthroughs that would prevent, slow, treat, or cure the disease. Furthermore, we know that communities of color and women face higher risk for the disease and experience barriers to treatment, care and research.

Congress has joined us in the fight and demonstrated a commitment to funding research for a pharmacological cure by increasing NIH funding for Alzheimer’s research from under $450 million in 2011 to $2.3 billion in 2019.

However, drug development has been more complicated than we could have ever predicted. As we work tirelessly to accelerate a cure, we are simultaneously doing everything we can to promote early detection, assessment, diagnosis and risk reduction. Congress has joined us on this mission too.

Last year, the BOLD Infrastructure for Alzheimer’s Act passed both the House and Senate with broad support and was signed into law by President TrumpDonald John Trump2020 Democrats spar over socialism ahead of first debate Senate passes .5 billion border bill, setting up fight with House 'Teflon Don' avoids the scorn of the 'family values' GOP — again MORE. Just last month, the Younger-Onset Alzheimer’s Disease Act was introduced.

Now, a group of leaders in the Congress have introduced a critical new piece of legislation – the Concentrating on High-Value Alzheimer’s Needs to Get to an End (CHANGE) Act. The bill was introduced by Sens. Shelley Moore CapitoShelley Wellons Moore CapitoPress beat lawmakers to keep trophy in annual softball game Bipartisan senators propose forcing EPA to set drinking water standard for 'forever chemicals' August recess under threat as yearly spending bills pile up MORE (R-W.Va.), Robert MenendezRobert (Bob) MenendezSenate to vote on blocking Trump's Saudi arms deal as soon as this week There is a severe physician shortage and it will only worsen Democrats ask Fed to probe Trump's Deutsche Bank ties MORE (D-N.J.), Debbie StabenowDeborah (Debbie) Ann Stabenow It's time to let Medicare to negotiate drug prices Trump judicial nominee says he withdrew over 'gross mischaracterizations' of record Trump judicial nominee withdraws amid Republican opposition: report MORE (D-Mich.) and Roger WickerRoger Frederick WickerHillicon Valley: Democratic state AGs sue to block T-Mobile-Sprint merger | House kicks off tech antitrust probe | Maine law shakes up privacy debate | Senators ask McConnell to bring net neutrality to a vote Lawmakers demand answers on Border Patrol data breach Senators call on McConnell to bring net neutrality rules to a vote MORE (R-Miss.), along with Reps. Linda SanchezLinda Teresa SánchezFirst major 'Medicare for All' hearing sharpens attacks on both sides We can accelerate a cure for Alzheimer's Dems press Mnuchin on Trump tax returns MORE (D-Calif.), Darren Lahood (R-Ill.), Cathy McMorris RodgersCathy McMorris RodgersOvernight Energy: Fight over fuel standards intensifies | Democrats grill Trump officials over rule rollback | California official blasts EPA chief over broken talks | Former EPA official says Wheeler lied to Congress EPA head clashes with California over how car emissions negotiations broke down Lawmakers celebrate 100th anniversary of women getting the right to vote MORE (R-Wash.) and Doris MatsuiDoris Okada MatsuiOvernight Health Care — Campaign for Tobacco-Free Kids — Poll finds Trump vulnerable on health care in battleground states | HHS must respond to petition on abortion referral ban by Thursday | Wyden presses health officials about CBD regulations Lawmakers map out path forward on Medicare Part D The Hill's Morning Report - In exclusive interview, Trump talks Biden, Iran, SCOTUS and reparations MORE (D-Calif.).

The CHANGE Act takes a targeted approach to addressing our nation’s Alzheimer’s crisis by encouraging early detection, diagnosis and access to interventions.

We have learned a great deal in recent years about Alzheimer’s disease. Most notably, cognitive decline is no longer an inevitability of aging. In fact, a recent study by the Lancet Commission found that “around 35 percent of dementia is attributable to a combination of the following nine risk factors: education to a maximum age of 11-12 years, midlife hypertension, midlife obesity, hearing loss, late-life depression, diabetes, physical inactivity, smoking and social isolation.”

In other words, more than one-third of dementia cases may be preventable through proactive actions taken to promote brain health across the lifespan and build cognitive resilience.

Additionally, we know that Alzheimer’s can be diagnosed as many as 20 years before symptoms appear. Early diagnosis affords a critical window in which measures taken to promote brain health can delay the onset of symptoms and improve quality of life through all stages of the disease for patients and their caregivers.

Underscoring the importance of early diagnosis, the Centers for Medicare and Medicaid Services (CMS) recently announced plans for 2020 that include financial incentives to screen for and identify individuals with dementias.

While CMS has recognized the importance of dementia detection, without policies in place to implement these tools, they will never realize their full potential, which makes the CHANGE Act so critical. CHANGE would incentivize and equip providers with the tools they need to accurately detect and diagnose Alzheimer’s at its earliest stages by directing CMS to require the use of cognitive impairment detection tools identified by the National Institutes of Health.

The bill would also direct CMS to incentivize the detection and diagnosis of Alzheimer’s disease or related dementias and promote care planning services, including the potential for clinical trial participation, which have historically had low levels of engagement, particularly within communities of color.

A shift in the provider system to focus heavily on brain health would spur a new understanding of its importance among Americans. More people will be aware that they may be able to minimize risk and delay the onset of Alzheimer’s and other dementias.

Moreover, with more Americans being diagnosed earlier and receiving education on the availability of clinical trials, we could see increased participation and diversity in trials, which may accelerate a pharmacological cure for Alzheimer’s.

I’m heartened that leaders in Congress are working together to solve what has become the greatest public health crisis of our time.

George Vradenburg is the co-founder and Chairman of UsAgainstAlzheimer’s.